With trailblazer 23andme Inc. re-emerging in the personal genomics space with a $115 million series E to reinvigorate its direct-to-consumer efforts and the price point for whole genome analysis falling below the important $1,000-per-person barrier, precision medicine (PM) has made its way into the everyday vernacular. Read More
With many of the big Pharma companies about to report their third quarter financial results in the coming days, investors and analysts will be keeping a close eye for clues on whether their senior executives give any indication about their M&A aspirations going forward. Read More
Antibody-drug conjugates (ADCs) may have fallen behind immunotherapy in the oncology-hype department, but plenty of companies are pressing forward with their ADC drugs. Last week, there was an entire conference – the 2015 World ADC Summit – held in San Diego dedicated to the discovery, development and manufacturing of ADCs. Read More
